FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1481615285> ?p ?o ?g. }

• W1481615285 endingPage "255" @default.
• W1481615285 startingPage "248" @default.
• W1481615285 abstract "Purpose: Screening interactions of a resolvin E1 analog (RX-10045) with efflux transporters (P-glycoprotein [P-gp], multidrug resistance-associated protein [MRP2], and breast cancer-resistant protein [BCRP]). Methods: Madin-Darby canine kidney cells transfected with P-gp, MRP2, and BCRP genes were selected for this study. [3H]-Digoxin, [3H]-vinblastine and [3H]-abacavir were selected as model substrates for P-gp, MRP2, and BCRP. Uptake and permeability studies across cell monolayer in both apical to basal (AP–BL) and BL–AP of these substrates were conducted in the presence of specific efflux pump inhibitors and RX-10045. Cell viability studies were conducted with increasing concentrations of RX-10045. Results: Uptake studies showed a higher accumulation in the presence of inhibitors (GF120918 and ketoconazole for P-gp; MK571 for MRP2; and β-estradiol for BCRP) as well as RX-10045. Similarly, dose-dependent inhibition studies demonstrated higher accumulation of various substrates ([3H]-digoxin, [3H]-vinblastine, and [3H]-abacavir) in the presence of RX-10045. IC50 values of dose-dependent inhibition of RX-10045 for P-gp, MRP2, and BCRP were 239±11.2, 291±79.2, and 300±42 μM, respectively. Cell viability assay indicated no apparent toxicity up to 350 μM concentration. Enhanced permeability for model substrates was observed in the presence of RX-10045. Uptake studies in human corneal epithelial cells suggest that RX-10045 is a strong inhibitor of organic cation transporter-1 (OCT-1). Conclusions: In summary, the resolvin analog (RX-10045) was identified as a substrate/inhibitor for efflux transporters (MRP2 and BCRP). Also, RX-10045 appears to be a strong inhibitor/substrate of OCT-1. Novel formulation strategies such as nanoparticles, nanomicelles, and liposomes for circumventing efflux barriers and delivering higher drug concentrations leading to a higher therapeutic efficacy may be employed." @default.
• W1481615285 created "2016-06-24" @default.
• W1481615285 creator A5028727820 @default.
• W1481615285 creator A5040297353 @default.
• W1481615285 creator A5047295889 @default.
• W1481615285 creator A5048846394 @default.
• W1481615285 creator A5058765978 @default.
• W1481615285 creator A5072119142 @default.
• W1481615285 date "2015-05-01" @default.
• W1481615285 modified "2023-10-16" @default.
• W1481615285 title "Interaction Studies of Resolvin E1 Analog (RX-10045) with Efflux Transporters" @default.
• W1481615285 cites W1534042983 @default.
• W1481615285 cites W1556464588 @default.
• W1481615285 cites W1963780604 @default.
• W1481615285 cites W1984297485 @default.
• W1481615285 cites W1992307218 @default.
• W1481615285 cites W1995307856 @default.
• W1481615285 cites W2009614034 @default.
• W1481615285 cites W2015696634 @default.
• W1481615285 cites W2020046608 @default.
• W1481615285 cites W2030565327 @default.
• W1481615285 cites W2033133387 @default.
• W1481615285 cites W2035308172 @default.
• W1481615285 cites W2047848796 @default.
• W1481615285 cites W2048710158 @default.
• W1481615285 cites W2053105710 @default.
• W1481615285 cites W2065262971 @default.
• W1481615285 cites W2074631079 @default.
• W1481615285 cites W2092825895 @default.
• W1481615285 cites W2095833330 @default.
• W1481615285 cites W2098693588 @default.
• W1481615285 cites W2106911056 @default.
• W1481615285 cites W2127130381 @default.
• W1481615285 cites W2137286226 @default.
• W1481615285 cites W2153553431 @default.
• W1481615285 cites W2158245905 @default.
• W1481615285 cites W2160165998 @default.
• W1481615285 cites W2162465757 @default.
• W1481615285 cites W4237613658 @default.
• W1481615285 doi "https://doi.org/10.1089/jop.2014.0144" @default.
• W1481615285 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4426295" @default.
• W1481615285 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25844889" @default.
• W1481615285 hasPublicationYear "2015" @default.
• W1481615285 type Work @default.
• W1481615285 sameAs 1481615285 @default.
• W1481615285 citedByCount "13" @default.
• W1481615285 countsByYear W14816152852015 @default.
• W1481615285 countsByYear W14816152852016 @default.
• W1481615285 countsByYear W14816152852017 @default.
• W1481615285 countsByYear W14816152852018 @default.
• W1481615285 countsByYear W14816152852019 @default.
• W1481615285 countsByYear W14816152852020 @default.
• W1481615285 countsByYear W14816152852021 @default.
• W1481615285 countsByYear W14816152852022 @default.
• W1481615285 crossrefType "journal-article" @default.
• W1481615285 hasAuthorship W1481615285A5028727820 @default.
• W1481615285 hasAuthorship W1481615285A5040297353 @default.
• W1481615285 hasAuthorship W1481615285A5047295889 @default.
• W1481615285 hasAuthorship W1481615285A5048846394 @default.
• W1481615285 hasAuthorship W1481615285A5058765978 @default.
• W1481615285 hasAuthorship W1481615285A5072119142 @default.
• W1481615285 hasBestOaLocation W14816152852 @default.
• W1481615285 hasConcept C104317684 @default.
• W1481615285 hasConcept C133936738 @default.
• W1481615285 hasConcept C149011108 @default.
• W1481615285 hasConcept C1491633281 @default.
• W1481615285 hasConcept C185592680 @default.
• W1481615285 hasConcept C200082930 @default.
• W1481615285 hasConcept C2778707650 @default.
• W1481615285 hasConcept C36201501 @default.
• W1481615285 hasConcept C44312359 @default.
• W1481615285 hasConcept C501593827 @default.
• W1481615285 hasConcept C512196 @default.
• W1481615285 hasConcept C53227056 @default.
• W1481615285 hasConcept C55493867 @default.
• W1481615285 hasConcept C86803240 @default.
• W1481615285 hasConcept C98274493 @default.
• W1481615285 hasConceptScore W1481615285C104317684 @default.
• W1481615285 hasConceptScore W1481615285C133936738 @default.
• W1481615285 hasConceptScore W1481615285C149011108 @default.
• W1481615285 hasConceptScore W1481615285C1491633281 @default.
• W1481615285 hasConceptScore W1481615285C185592680 @default.
• W1481615285 hasConceptScore W1481615285C200082930 @default.
• W1481615285 hasConceptScore W1481615285C2778707650 @default.
• W1481615285 hasConceptScore W1481615285C36201501 @default.
• W1481615285 hasConceptScore W1481615285C44312359 @default.
• W1481615285 hasConceptScore W1481615285C501593827 @default.
• W1481615285 hasConceptScore W1481615285C512196 @default.
• W1481615285 hasConceptScore W1481615285C53227056 @default.
• W1481615285 hasConceptScore W1481615285C55493867 @default.
• W1481615285 hasConceptScore W1481615285C86803240 @default.
• W1481615285 hasConceptScore W1481615285C98274493 @default.
• W1481615285 hasIssue "4" @default.
• W1481615285 hasLocation W14816152851 @default.
• W1481615285 hasLocation W14816152852 @default.
• W1481615285 hasLocation W14816152853 @default.
• W1481615285 hasLocation W14816152854 @default.
• W1481615285 hasOpenAccess W1481615285 @default.

• next